Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies.
- Published: 01 Apr 2018 Journal: Oncolytic Virotherapy (issn: 2253-1572,
Copyright policy)
- Publisher: Dove Press
- Tangshan Normal University China (People's Republic of)
- 1
- 2
1. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 1991;72(Pt 2):439-442. [OpenAIRE]
2. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893-897.
3. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75(2):295-305. [OpenAIRE]
4. Mühlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature. 2011;480(7378):530-533.
5. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011;7(8):e1002240. [OpenAIRE]
6. Malvoisin E, Wild TF. Measles virus glycoproteins: studies on the structure and interaction of the haemagglutinin and fusion proteins. J Gen Virol. 1993;74(Pt 11):2365-2372. [OpenAIRE]
7. de Swart RL,Yüksel S, Osterhaus AD. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol. 2005;79(17):11547-11551. [OpenAIRE]
8. Bouche FB, Ertl OT, Muller CP. Neutralizing B cell response in measles. Viral Immunol. 2002;15(3):451-471.
9. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919-4926.
10. Robinson S, Galanis E. Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther. 2017;17(3):353-363.
11. Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood. 2014;123(9):1327-1335.
12. Wei J, Wahl J, Nakamura T, et al. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas. Gene Ther. 2007;14(22):1573-1586.
13. Muharemagic D, Zamay A, Ghobadloo SM, et al. Aptamer-facilitated protection of oncolytic virus from neutralizing antibodies. Mol Ther Nucleic Acids. 2014;3:e167. [OpenAIRE]
14. Langfield KK, Walker HJ, Gregory LC, Federspiel MJ. Manufacture of measles viruses. Mol Biol. 2011;737:345-366. [OpenAIRE]
15. Phillips BA. In vitro assembly of polioviruses. I. Kinetics of the assembly of empty capsids and the role of extracts from infected cells. Virology. 1969;39(4):811-821.
- 1
- 2
Related research
- Tangshan Normal University China (People's Republic of)
- 1
- 2
1. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 1991;72(Pt 2):439-442. [OpenAIRE]
2. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893-897.
3. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75(2):295-305. [OpenAIRE]
4. Mühlebach MD, Mateo M, Sinn PL, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature. 2011;480(7378):530-533.
5. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011;7(8):e1002240. [OpenAIRE]
6. Malvoisin E, Wild TF. Measles virus glycoproteins: studies on the structure and interaction of the haemagglutinin and fusion proteins. J Gen Virol. 1993;74(Pt 11):2365-2372. [OpenAIRE]
7. de Swart RL,Yüksel S, Osterhaus AD. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol. 2005;79(17):11547-11551. [OpenAIRE]
8. Bouche FB, Ertl OT, Muller CP. Neutralizing B cell response in measles. Viral Immunol. 2002;15(3):451-471.
9. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919-4926.
10. Robinson S, Galanis E. Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther. 2017;17(3):353-363.
11. Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood. 2014;123(9):1327-1335.
12. Wei J, Wahl J, Nakamura T, et al. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas. Gene Ther. 2007;14(22):1573-1586.
13. Muharemagic D, Zamay A, Ghobadloo SM, et al. Aptamer-facilitated protection of oncolytic virus from neutralizing antibodies. Mol Ther Nucleic Acids. 2014;3:e167. [OpenAIRE]
14. Langfield KK, Walker HJ, Gregory LC, Federspiel MJ. Manufacture of measles viruses. Mol Biol. 2011;737:345-366. [OpenAIRE]
15. Phillips BA. In vitro assembly of polioviruses. I. Kinetics of the assembly of empty capsids and the role of extracts from infected cells. Virology. 1969;39(4):811-821.
- 1
- 2